Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
|Videos|May 25, 2017
Dr. Shah on Status of CAR T-cell Therapies in ALL
Author(s)Bijal D. Shah, MD
Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).
Advertisement
Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).
The first FDA approval will likely be in pediatric ALL, Shah says. However, in the adult patients with ALL, researchers are closely behind.
However, several pharmaceutical companies have been entering the space and are actively conducting clinical trials with these agents. These therapies have the ability to produce durable remissions and improve survival, Shah says.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.
MT027, an off-the-shelf B7-H3–directed CAR T-cell therapy, earned FDA fast track designation for recurrent glioblastoma.
The selective ROCK2 inhibitor TDI01 generated organ-wide responses in previously treated moderate-to-severe chronic graft-versus-host disease, with the 400-mg dose performing best.
Dosing adjustments of ponatinib based on responses increased tolerability in patients with chronic myeloid leukemia according to OPTIC.
Patients who received MBTF prior to allo-HSCT achieved promising survival outcomes and manageable safety in relapsed/refractory acute myeloid leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
The OncFive: Top Oncology Articles for the Week of 8/30
5